Related Experiment Videos
[Inhibitors of neoangiogenesis in antineoplastic therapy]
1Zakład Immunologii Nowotworów Instytutu Immunologii i Terapii Doświadczalnej PAN im. L. Hirszfelda we Wrocławiu.
Abstract:
The role of angiogenesis in tumor growth and metastasis is discussed. The endogenous activators and inhibitors of tumor angiogenesis are presented and their mechanisms of action are reviewed. An overview on angiogenesis as a new potential target of antitumor therapy is described. The clinical trials of various antiangiogenic agents are briefly summarized and their differential mechanisms of action are discussed.
Insights
Angiogenesis, the formation of new blood vessels, fuels tumor growth and spread. Targeting this process with antiangiogenic agents offers a promising new strategy for cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Context:
- Tumorigenesis is a complex process heavily reliant on the development of new blood vessels.
- Understanding the intricate balance of pro-angiogenic and anti-angiogenic factors is crucial in oncology.
- Tumor angiogenesis plays a pivotal role in tumor progression, invasion, and metastasis.
Purpose:
- To review the endogenous activators and inhibitors of tumor angiogenesis.
- To elucidate the mechanisms of action for key angiogenic factors.
- To explore the therapeutic potential of targeting angiogenesis in cancer treatment.
Summary:
- Discusses the critical role of angiogenesis in tumor growth and metastasis.
- Presents endogenous activators and inhibitors of tumor angiogenesis, detailing their mechanisms.
- Provides an overview of angiogenesis as a potential target for antitumor therapy.
- Summarizes clinical trials of antiangiogenic agents and their distinct mechanisms.
Impact:
- Highlights angiogenesis as a validated therapeutic target in oncology.
- Informs the development of novel antiangiogenic drugs and treatment strategies.
- Contributes to a deeper understanding of tumor biology and treatment resistance.